Skip to main content

Table 4 Number (%) of study patients reporting AEs (safety population)

From: Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease

Preferred term

PBO MDI

GP MDI

GP MDI

GP MDI

GP MDI

TIO

n = 21

14.4 μg

28.8 μg

57.6 μg

115.2 μg

18 μg

n (%)

n = 21

n = 23

n = 21

n = 21

n = 22

  

n (%)

n (%)

n (%)

n (%)

n (%)

One or more AEs

4 (19.0)

3 (14.3)

3 (13.0)

5 (23.8)

3 (14.3)

4 (18.2)

Dry mouth

2 (9.5)

1 (4.8)

0

3 (14.3)

1 (4.8)

2 (9.1)

Oropharyngeal pain

0

1 (4.8)

0

0

1 (4.8)

0

Bronchospasm paradoxical

0

0

0

0

1 (4.8)

0

Nasopharyngitis

0

0

0

1 (4.8)

0

0

Urinary tract infection

0

0

0

1 (4.8)

0

0

Vessel puncture site hematoma

0

0

1 (4.3)

0

0

1 (4.5)

Sinusitis

0

0

1 (4.3)

0

0

0

Headache

0

0

1 (4.3)

0

0

0

Insomnia

0

0

1 (4.3)

0

0

0

Dyspnea

0

0

1 (4.3)

0

0

0

Hypertension

0

0

1 (4.3)

0

0

0

Dizziness

0

1 (4.8)

0

0

0

0

Cough

0

1 (4.8)

0

0

0

0

Diarrhea

0

0

0

0

0

1 (4.5)

Umbilical hernia

1 (4.8)

0

0

0

0

0

Gastroenteritis

1 (4.8)

0

0

0

0

0

Gastrointestinal viral infection

1 (4.8)

0

0

0

0

0

  1. AE = adverse event; DPI = dry powder inhaler GP MDI=glycopyrronium metered-dose inhaler; PBO = placebo; TIO = tiotropium.